Cytokines in clinical cancer immunotherapy.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. · 2019

Read Cytokines in clinical cancer immunotherapy. by Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6325155.txt.

Description

Berraondo and co-authors review cytokines as drugs in cancer immunotherapy. Their review appeared in the British Journal of Cancer. Cytokines are small proteins that pass messages between cells. Some showed strong anti-tumor effects in animal tests. Two early drugs, interferon-alpha and interleukin-2, won approval. Their benefit stayed modest for most patients.

Interest in cytokines has surged again since then. Many trials now test them alone or in drug pairs. New designs give known molecules fresh ways to act. Fusion proteins keep them active longer in the body. Others aim the signal at tumors or chosen immune cells. Blocking harmful suppressive cytokines is a parallel plan. The review sorts these second-generation approaches and their trial status.

Catalog record

CREATORBerraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE66 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6325155

Browse the full library · About the Tower of Babel